Testing the potential of citrate-capped Mn 3 O 4 nanoparticles (NPs) as a therapeutic agent for alternative rapid treatment of hyperbilirubinemia through direct removal of bilirubin (BR) from blood in mice. Materials & methods: NPs were synthesized and the mechanism of BR degradation in presence and absence of biological macromolecules were characterized in vitro. To test the in vivo BR degradation ability of NPs, CCl 4 -intoxicated mice were intraperitoneally injected with NPs. Results: We demonstrated ultrahigh efficacy of the NPs in symptomatic treatment of hyperbilirubinemia for rapid reduction of BR in mice compared with conventional medicine silymarin without any toxicological implications. Conclusion: These findings may pave the way for practical clinical use of the NPs as safe medication of hyperbilirubinemia in human subjects.
The term hyperbilirubinemia is defined as increased bilirubin (BR) level (>1.3 mg/dl in human) in blood. Hyperbilirubinemia is caused when there is an imbalance between production of BR (resulting from hemolysis, sepsis, blood extravasation or polycythemia) and decrease in BR excretion due to inadequate hepatic conjugation and increased enterohepatic reabsorption (resulting from pyloric stenosis, delayed bacterial gut colonization, GI tract immobility or obstruction) [1] [2] [3] . Although at micromolar concentrations BR acts as an antioxidant for scavenging peroxyl radicals in blood [4] , yet it can be toxic and harmful to cells at higher concentration [5, 6] . Elevated level of BR and its oxidative products in human blood causes various diseases including neonatal jaundice (>10 mg/dl), Gilbert syndrome (with BR level reaching >6 mg/dl), Crigler-Najjar type I disease (>30 mg/dl) [7] and BR-induced neurologic dysfunction [8] .
Severe neurotoxicity in case of neonates (Kernicterus) and damage in white matter of adult brain are also the consequences of higher BR level [9, 10] . In case of hepatitis E, infection in pregnant women, associated hyperbilirubinemia itself is found to increase the risk of preterm delivery [11] . Treatment options for hyperbilirubinemia include phototherapy [12] , hemoperfusion, hemodialysis and exchange blood transfusion [13] . Although phototherapy is widely used and a best choice for the treatment of hyperbilirubinemia in neonates, its efficacy is noted to diminish as children with Crigler-Najjar syndrome advance in age and in particular during adolescence [12, 14, 15] . Hemoperfusion and exchange blood transfusion have significant morbidity and even mortality [1] . Apart from the mentioned therapeutic procedures various organic, inorganic and phytochemicals have been used for reduction of elevated BR level in blood [16] [17] [18] [19] . All these therapeutic drugs function in hepatoprotective way and lack the ability to degrade BR directly [2] . So, none of these became very fruitful in effective and quick reduction of serum BR level. In the above context, a safe, symptomatic and effective therapeutic strat- Manganese (Mn), one of the safest materials is a natural constituent, and often a cofactor for enzymes and receptors [20] . In a series of earlier studies from this group, we have established that the charge state of Mn in the citrate-capped Mn 3 O 4 nanoparticles (C-Mn 3 O 4 nanoparticles [NPs] ) is involved in selective catalysis of BR in absence of any photoactivation [21, 22] . The mixed valence state of Mn (+2, +3 and +4) along with the functional groups on the surface coordinating ligands of Mn 3 O 4 NPs leads to the exceptional catalytic activity. The very fast and selective reduction of the BR level (both conjugated and unconjugated) in the blood specimens in ex vivo condition without any significant alteration of other essential blood parameters have also been reported.
In the present study, we have synthesized citratecapped Mn 3 O 4 NPs by ligand-etching technique as described in earlier studies [21, 23] . The structural characterization and the interaction with a model-blood protein of the NPs have been performed using high resolution transmission electron microscopy (TEM), steady state and time-resolved optical spectroscopy. Ultrahigh efficacy of generation of reactive oxygen species (ROS) and surface-mediated catalysis of the synthesized NPs, have also been established. We have also performed systematic in vitro and in vivo preclinical studies on the toxicity of the functionalized NPs. All the measurements confirm that the Mn-based nanomedicine is safe and biocompatible due to lack of any potential toxicity. In order to assess the effectiveness of the NPs as symptomatic nanomedicine in managing hyperbilirubinemia in mice, we have checked the BR concentration and found to become almost normal in 6 h after intraperitoneal injection of the NPs. Therefore, these results demonstrate that the functionalized NPs are strong candidate as effective drug for hyperbilirubinemia treatment, and superior to the commercially available drug, silymarin in terms of efficacy with a satisfactory biocompatibility.
Materials & methods

Materials
Manganese chloride, sodium citrate, NaOH, BR, human serum albumin (HSA), silymarin, heparin, acrylamide, bis-acrylamide, ammonium persulfate, isobutanol, tris base, bromophenol blue, dithiothreitol, tetramethylethylenediamine were obtained from Sigma-Aldrich (MO, USA). 2′, 7′-dichlorofluorescin diacetate (DCFH-DA), Ethanol amine, HCl and glycerol were received from Merck (NJ, USA). All the chemicals used for this study were of analytical grade and were used without further purification.
Synthesis of citrate-functionalized Mn 3 O 4 NPs
Synthesis of bulk Mn 3 O 4 NPs was done following a reported ultrasonic-assisted approach for preparation of colloidal Mn 3 O 4 NPs at normal temperature and pressure without any additional surfactants or templates [23] . For functionalizing the as-prepared Mn 3 O 4 NPs by citrate ligand first, 0.5 M citrate (ligand) solution was prepared in Milli-Q (from Millipore) water. Then, the pH of the solutions at approximately seven was adjusted by drop wise addition of 1 (M) NaOH solution. In the ligand solution of pH approximately seven, as-prepared Mn 3 O 4 NPs (∼100 mg of powder Mn 3 O 4 NPs in 5 ml ligand solution) were added and extensively mixed for 12 h in a cyclomixer. Finally, using a syringe filter of 0.22 μm diameter the nonfunctionalized bigger-sized NPs were filtered out. The resulting filtrated solutions were used for our experiments, both in vivo and in vitro studies without further dilution [21] .
Microscopic & spectroscopic studies
For the characterization of the NPs, TEM samples were prepared by dropping sample stock solutions onto a 300-mesh carbon-coated copper grid and dried overnight in air. Particle sizes were determined from micrographs recorded using an FEI TecnaiTF-20 fieldemission high-resolution transmission electron microscope operating at 200 kV. Optical absorbance spectra of the solutions were recorded using a quartz cuvette of 1 cm path length in Shimadzu Model UV-2600 spectrophotometer. For the fluorescence imaging study of liquid NPs, Olympus BX51 fluorescence microscope was used. Jobin Yvon Model Fluoromax-3 Fluorimeter was used to study the characteristic fluorescence excitation and PL spectra of C-Mn 3 O 4 NP solutions. Far UV circular dichroism measurements were performed on a JASCO815 spectrometer (from JASCO International Co. Ltd, Tokyo, Japan) by using a 1 cm path-length quartz cell. Fluorescence transients were measured using the 16-channel time-correlated singlephoton counting (TCSPC) setup, assembled in the lab with all the components (16-channel PMT module PML-16-1-C, Simple Tau-130EM with SPC-130EM & DCC-100 cards, Express Card 54 and SPCM64 software preinstalled in Lenovo ThinkPad laptop-PC) from Becker & Hickl (Berlin, Germany).
For 283-nm laser excitation, we used a femtosecond coupled TCSPC setup [24] . Briefly, the samples were excited by the third harmonic laser beam (283 nm) of the 850 nm (0.5 nJ per pulse) by using a mode-locked Ti-sapphire laser with an 80 MHz repetition rate (Tsunami, Spectra Physics), pumped by a 10W Millennia (Spectra Physics) followed by a pulse-picker (rate 8 MHz), and a third harmonic generator (Spectra-Phys- The quality of the curve fitting is evaluated by a reduced chi-square and residual data.
Other measurements
In order to investigate the efficacy of the NPs for the generation of ROS, DCFH (dichlorofluorescein) was prepared from DCFH-DA at room temperature by mixing 0.5 ml of 1.0 mM DCFH-DA in methanol with 2.0 ml of 0.01N NaOH [25] [26] [27] . The solution was then neutralized with 10 ml of 25 mM NaH 2 PO 4 , at pH 7.4 and was kept on ice in the dark until use. Native gel electrophoresis studies intend to discriminate between HSA and HSA-NP (after 12 and 24 h of incubation) was performed using native PAGE. The gel was prepared according to standard procedures [11] , without the addition of SDS or β-mercaptoethanol. Gradient in the gel was nonlinear. Electrophoresis was conducted in denaturing condition for about 3 h in a vertical apparatus (Aplex 305II) at room temperature, at 120V. After completion, protein bands were stained using Coomassie blue.
Animals
Swiss albino mice of either sex (5-8-weeks old, weighing 28 ± 4 gm) were procured from a Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) approved animal house (registration number: 50/PO/99/CPCSEA) and housed in standard, clean polypropylene cages in a temperature controlled animal room (temperature 22 ± 3°C; relative humidity 45-60 ± 1%; 12 h light/ dark cycle). Water and standard laboratory pellet diet for mice (Hindustan Lever, Kolkata) were available ad libitum. All mice were allowed to acclimatize for 1 week prior to experimentation. The animals were maintained according to the guidelines recommended by CPCSEA, New Delhi, India and approved by the Institutional Animal Ethics Committee (Approval number-JU-Dey's/IAEC/09/14, dated 31.01.2014).
Acute toxicity study
Single-dose intraperitoneal toxicity study was conducted to determine the possible acute toxicity of surface-modified Mn 3 O 4 NPs following the general principles of the OECD guideline 423 with some adjustments [28] . Twelve female mice were divided in four groups: one control group (received 0.2 ml Milli-Q water) and three experimental groups (received either 600, 2000 or 5000 mg/kg bodyweight (BW) of NP dissolved in 0.2 ml Milli-Q water). All the animals were kept in fasting condition overnight prior to the injection. Behavior, mortality and BW were monitored daily for a period of 14 days.
Treatment protocol: Phase I
Forty eight mice of either sex were randomly divided into six groups of eight mice each. Group I served as the vehicle control and was given olive oil daily (0.5 ml/kg BW) for a period of 2 weeks. Group III served as NP control and left untreated for first 2 weeks, then received citrate-capped Mn 3 O 4 NP (500 mg/kg BW dissolved in 0.2ml Milli-Q water) daily for last 7 days. For inducing hyperbilirubinemia and hepatotoxicity (in vivo), animals of groups II, IV, V and VI were administered with carbon tetrachloride solution (50% CCl 4 in olive oil) 1 ml/kg BW daily for a period of 2 weeks. CCl 4 is a well-known hepatotoxic agent frequently used to study hepatoprotective activity of new drugs in in vivo experimental model. CCl 4 administration induces critical liver damage in mice which in turn simulates a condition of acute hepatitis showing similar symptoms as humans [29] [30] [31] . CCl 4 activated by liver enzyme cytochrome P450 forms the trichloromethyl free radical (CCl 3 •) that damages hepatic cells [32] . These radicals bind covalently to sulfhydryl groups of glutathione and protein thiols in cells to initiate a chain of events leading to membrane-lipid peroxidation and cell necrosis [33] [34] [35] . After CCl 4 intoxication, group III served as the CCl 4 control and was left untreated. Group IV was administered with citrate-capped Mn 3 O 4 NP (500 mg/kg BW dissolved in 0.2 ml Milli-Q water) for 7 days. Group V served as citrate control and was treated with citrate (100 μl/mice; 1:1 solution in water). Group VI served as the positive control and was administered silymarin (100 mg/kg BW) [36, 37] daily for a period of 1 week. All the treatments were executed by intraperitoneal injection. At the end of the experiment, the animals were 
Measurement of serum biochemical parameters
For biochemical studies, blood samples were collected just before sacrifice in sterile tubes (nonheparinized) from retro-orbital plexus and allowed to clot for 45 min. Serum was separated by centrifugation at 3000 rpm for 15 min. All serum samples were sterile, hemolysis-free, and were kept at 4°C before determination of the biochemical parameters. Serum BR concentration (total and direct) was measured using commercially available test kits and results were expressed as mg/dl. Liver damage was assessed by the estimation of serum activities of alanine aminotransferase (ALT, EC 2.6.1.2), aspartate aminotransferase (AST, EC 2.6.1.1), and alkaline phosphatase (ALP, EC 3.1.3.1), γ-glutamyltranferase (GGT, 2.3.2.2) using commercially available test kits. The results were expressed as units/liter (IU/l). Total protein concentration was estimated and expressed as gm/dL. All the kits for measurement of serum biochemical parameters were purchased from Autospan Liquid Gold, Span Diagnostics Ltd (Surat, India). All hematological tests were performed spectrophotometrically following the protocols described by the corresponding manufacturers.
Hematological study
For hematological studies, the blood was collected in heparinized tubes. Blood-cell count was done using blood smears in Sysmax-K1000 Cell Counter. Parameters studied were hemoglobin, total red blood cell, reticulocyte, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelets, total white blood cell.
Histopathological examination
The liver was excised immediately after collection of blood, washed with ice-cold phosphate buffer and dried with tissue paper. It was weighed and fixed in neutral formalin solution (10%), dehydrated in graduated ethanol (50-100%), cleared in xylene and embedded in paraffin. Sections 4-5 μm thick were prepared using microtome and then stained with hematoxylin and eosin (H&E) dye and examined for histopathological changes under the microscope.
Statistical analysis
All quantitative data are expressed as mean ± standard deviation. Comparison of different parameters between the groups was performed using one-way analysis of variance followed by Tukey's multiple comparison test using a computer program GraphPad Prism (version 5.00 for Windows), GraphPad Software, California, USA [38] . p < 0.05 was considered significant.
Results & discussion
The spherical Mn 3 O 4 NPs were imaged by TEM ( Figure 1A ) and statistical evaluation found a size distribution of about 3.69 ± 0.12 nm ( Figure 1B) . Figure 1C is the high resolution TEM image of an isolated Mn 3 O 4 NP. The observed interfringe distance of 0.314 nm is consistent with Mn 3 O 4 interplanar distance of 112 plane revealing crystalline nature of the NP [21] .
The absorbance spectra of the NPs and the cappingligand citrate are represented in Figure 1D . A magnified view of the absorption spectrum of the NPs in the range of 400-800 nm is shown in the inset Figure 1Di .
The absorbance maxima at around 290 and 429 , 526, 746 nm correspond to the high-energy ligandto-metal charge transfer transition involving citrateMn 4+ interaction and Jahn-Teller (J-T) distorted d-d transitions centered over Mn 3+ ions respectively [21, 22] . The NPs are also found to be fluorescent under various excitation wavelengths as reported earlier [21] . A fluorescence microscopic image containing bright field and fluorescence from the NPs solution under UV (365 nm), blue (436 nm) and green (546 nm) excita- tion is shown in the inset Figure 1Dii . The corresponding emission spectra of the NPs solution are shown in Figure 1Diii , revealing distinct emission peaks for different excitation wavelengths. Different peaks in the excitation spectra (Figure 1Div) form the solution for different detection wavelengths, confirm the multiple excited state in the emission from the NPs as detailed in earlier literature [21] . In order to investigate the efficacy of the NPs in BR degradation in vitro, we have monitored BR decomposition at pH = 7.4 in presence and absence of the serum protein HSA (Figure 2A) . We have maintained the concentration of the NPs similar to that used in the in vivo experiment (from same stock solution). The characteristic absorbance of BR at 450 nm has been chosen for monitoring the kinetic study using UV-visible spectroscopy. Figure 2A shows the relative concentration (C t /C 0 ) of BR plotted against reaction time. In absence of HSA, decomposition of BR after 60 min by the NPs can be observed to be around 80%, whereas in presence of HSA, the decomposition reduced to 40%. In contrast to the catalytic decomposition of BR, Symptomatic nanomedicine for hyperbilirubinemia Research Article only 2-5% of BR degradation is observed without the NPs. These results are self-explanatory, since the water soluble BR gets either higher chance to interact with NPs than in the albumin protein or more accessible to the NPs-generated radical in the aqueous solution [21] .
Here, we have found that the NPs are efficient generator of ROS in aqueous solution. Enhanced emission of an ROS indicator DCFH is used for the monitoring of oxidative stress in the solution. The emission maxima of DCFH (520 nm) upon excitation at λ ex =488 nm was plotted against time to generate the fluorescence kinetic plot ( Figure 2B ) for repetitive addition of DCFH in the solution. The NPs were capable of producing ROS for at least eight cycles as highlighted in Figure 2Bi . The reduction in oxidative stress generation has also been observed in presence of well-known ROS quencher ethanol [21] in the medium (Figure 2Bii ). Figure 2C clearly indicates that the generated ROS was inefficient to degrade the BR with increased level of ethanol concentration.
The observed reduction efficacy of the NPs in presence of HSA (Figure 2A ) could be rationalized in the following two ways. First, the BR may interact directly with the NPs and undergoes surface-mediated catalysis (Langmuir-Hinshelwood type) and encapsulation of the BR in the presence of HSA hinders the interaction leading to less degradation of BR. Second, the NPs could be encapsulated by the protein HSA for the less interaction with the BR in the aqueous solution. We have ruled out the first possibility by an attempt to study the rate of BR degradation kinetics with the concentration of the NPs in the solution. The rate of the kinetics was found to be independent of the NPs concentration, which should not be the case of surfacemediated catalysis. In order to address the second possibility, we have investigated the interaction of the NPs with the protein HSA as shown in Figure 3 . The far-UV circular dichroism spectra of HSA, exhibited two negative bands in the UV region at 208 and 220 nm ( Figure 3A) , characteristic of an α-helical structure of protein [39] . The percentage of helix content of HSA both in presence and absence of NPs is found to be similar revealing insignificant conformational alteration in α-helical structure of HSA in presence of the NPs. The molecular mass of the protein HSA in presence of the NPs is also found to be intact as shown in native gel electrophoresis study ( Figure 3B resonance energy transfer (FRET) [40] as a result of strong spectral overlap of the Trp-214 emission with the absorption of the NPs ( Figure 1D ). Insignificant change in the Trp-214 emission transient in presence of the NPs, clearly rules out proximal interaction of the protein with the NPs.
For assessing the maximal-tolerated dose of surfacefunctionalized Mn 3 O 4 NP, we performed single-dose acute toxicity study as per OECD guideline. Intraperitoneal injection of Mn 3 O 4 NP did not cause any mortality throughout the experimental period for all three dose groups. Behavioral and physical symptoms of acute toxicity such as decreased activity or decreased uptake of food and water were not also been observed during the study period. As no clinical signs of toxicity were observed upto 5000 mg/kg BW, hence 1/10th of the maximum dose administered (i.e., 500 mg/kg BW) was selected for the present study.
In the phase I study, the total serum BR (Tsb) level of CCl 4 treated group (group II) increased to 0.89 ± 0.07 mg/dl which is far higher than the control group (group I; 0.32 ± 0.04 mg/dl), indicative of hyperbilirubinemia. This group (group II) was left untreated for a week to see the auto recovery. The serum biochemical tests were done after treatment of seven days and represented in Table 1 . The results show that treatment with the NPs significantly decreased BR level (total and direct) even lower than the sham control ( Figure 4A & B) . But for group II, we have seen very mild decrease in serum BR concentration even after removal of the hepatoxin, indicating slow recovery process. However, in case of direct BR level, the reduction is not significantly different from the clinical standard silymarin (Table 1) . The NPs directly interacts with the BR and degrade the same. In the case of direct BR (soluble in aqueous environments and complex with glucuronic acid), hindrance of the interaction with NPs could be a possible reason of lower efficacy of the NP in reducing direct BR.
For assessing the efficiency of BR degradation in vivo by NPs over standard drug silymarin, we performed the second phase of experiment. Here, BR concentration was monitored for a period of 24 h after intoxication. Three weeks CCl 4 intoxication increased the total serum BR level upto 1.28 ± 0.14 mg/dl. Single dose of Mn 3 O 4 NP decreases Tsb to 0.40 ± 0.07 mg/dl within 2 h and back to normal level (0.32 ± 0.05 mg/dl) within 6 h compared with the silymarin treated group 1.22 ± 0.16 mg/dl (2 h) and 1.10 ± 0.14 mg/dl (6 h), respectively. The results are represented in Figure 4C & D. Treatment with NPs decreased Tsb level almost 70% compared with that of silymarin (8%) in 2 h and restored normal Tsb concentration within 6 h. The results suggest the efficiency of citratefunctionalized Mn 3 O 4 NP in targeted degradation of BR in a much faster rate compared with that of standard drug silymarin in in vivo experimental system.
For assessment of liver injury, serum activity of various hepatic lysosomal enzymes is used as diagnostic indicators [41] . Earlier studies have shown that CCl 4 administration increases serum levels of AST, ALT, ALP and GGT [16] [17] [18] [19] [42] [43] [44] [45] . Normal liver contains high concentrations of these enzymes. When there is hepatocyte necrosis or membrane damage, these enzymes are released into the circulation, as indicated by elevated serum enzyme levels [46] . The hepatotoxicity of CCl 4 was confirmed in our study by a significant elevation of serum ALT (197.86%), AST (157.63%), ALP (106.77%) and GGT (105.36%) activities in the CCl 4 -treated group as compared with the vehicle control which are summarized in Table 2 . However, treatment with NPs at a dose of 500 mg/kg BW for 7 days Table 2 . The hematological status of animals of group I, group II, group III and group IV has been assessed and are given in the Table 3 . It is evident that there is insignificant change in the hematological parameters across the four groups. The result clearly shows that the presence of NPs does not affect hematological system.
The histopathological observations also support the results obtained from serum biochemical assays ( Figure 5 ). The liver lobules of the vehicle control animals (group I) showed a classical structure with hepatocyte plates directed from the portal triads toward the central vein, where they freely anastomose. The liver sinusoids are normally irregularly dilated and spaces of Disse can be seen. The liver sections of this group showed normal hepatic cells, that is, with wellpreserved cytoplasm and prominent nucleus, nucleolus (Figure 5i ). The livers of CCl 4 -intoxicated mice (group II, Figure 5ii ) revealed moderate to severe hepatocellular vacuolization, hepatic necrosis and swelling, bile-duct hyperplasia and increasing cellular mitosis as well as dilation of Disse spaces with focal disruption of the sinusoidal endothelium, inflammatory infiltrations of the portal triads (Figure 5ii) and distortion of the central venules. Mononuclear cell infiltration, hemor-rhage, fatty degeneration and formation of regenerative nodules were also observed in CCl 4 -treated group indicating that CCl 4 induced severe damage to the hepatic cells. The animals treated with NPs (group IV) and silymarin (group VI) (Figure 5iv & vi, respectively) revealed slight to mild hepatocellular vacuolation and better preservation of the normal liver architecture, with moderate hepatocyte plate disorganizations and smaller dilations of Disse spaces. These treated animals displayed rare periportal inflammatory infiltrate in the liver lobules. The animals treated with only NPs (group III) showed normal liver architecture comparable with the vehicle control group. This indicates the nontoxic effect of citrate-capped Mn 3 O 4 on hepatocytes which are in good correlation with the liver function tests. It has been reported that CCl 4 causes necrosis, [42, [47] [48] [49] [50] fibrosis, [47, [51] [52] [53] mononuclear cell infiltration, [49, 53] steatosis and foamy degeneration of hepatocytes, increase in mitotic activity [54] and cirrhosis [42, 49] in liver. Therefore, our histopathological findings in the liver due to CCl 4 administration are in agreement with previous studies. However, treatment with NPs significantly decreased these hepatotoxicity characteristics in mouse liver, suggesting that NPs provided protection against CCl 4 -induced liver injury. So, according to the microscopic examinations, severe liver damage induced by CCl 4 was remarkably reduced by the administration of the NPs, which was in good correlation with the results of the liver-functional parameters of the serum.
Conclusion
We have synthesized the NPs with the ultrahigh efficacy toward degradation of BR by a simple and green solution-based technique. We further demonstrated Symptomatic nanomedicine for hyperbilirubinemia Research Article that these Mn-based NPs are safe, biocompatible and effective-targeted probes for hyperbilirubinemia in mice model based on the in vitro and in vivo assessments, especially without any toxicological implications. The study to compare the efficacy of the NPs with that of a commercially available drug silymarin shows that in hyperbilirubinemia mice, administration of the NPs brings the BR level to normal limits in 6 h whereas silymarin needs several days to control hyperbilirubinemia in mice. The overall therapeutic procedure is pictorially presented in Figure 6 . These findings break through the bottleneck in therapeutic procedures for the treatment of hyperbilirubinemia by fast and direct degradation of BR and pave the way for the practical clinical therapy of Mn-based NPs as safe nanomedicines.
Future perspective
In the years to come, advances in engineering nanomaterials with exquisite size and shape control will expand their use in biomedical applications and open the door of personalized medicine. Our study has shown the potential use of Mn-based NPs directly as therapeutic agent against hyperbilirubinemia. The targeted in vivo BR degradation ability of surface-functionalized 
Executive summary
Background
• Hyperbilirubinemia is one of the most common diseases in tropical countries causing several neurologic damages for neonates as well as adults and if untreated may lead to morbidity and even mortality.
• Current therapeutics for hyperbilirubinemia are poorly effective, nontargeted and time consuming. Also there is no medicine available which can degrade bilirubin directly in in vivo condition.
Outcomes of the study
• In this study, the authors demonstrate that intraperitoneally injected citrate-functionalized Mn 3 O 4 nanoparticles (NPs) degrade bilirubin very fast and in a specific, nontoxic way compared with conventional drugs in a mouse model.
Methods
• Synthesis and characterization of citrate-functionalized Mn 3 O 4 NPs have been done.
• The in vitro catalytic activity of NPs in degradation of bilirubin through reactive oxygen species mechanism has been established.
• In vivo preclinical studies of Mn 3 O 4 NPs as a therapeutic agent against hyperbilirubinemia were done using mice as a model organism.
• The efficiency of Mn 3 O 4 NPs in treatment of hyperbilirubinemia in mice is ensured by biochemical tests and histopathological studies.
Conclusion & future perspective
• Our results confirmed that Mn-based NPs are nontoxic, biocompatible and effective targeted probes against hyperbilirubinemia.
• This study may open a new door for faster, safer and efficient therapeutic treatment of hyperbilirubinemia, jaundice and associated diseases.
• This approach may be applied for future nanomedicine applications.
future science group Symptomatic nanomedicine for hyperbilirubinemia Research Article bilirubinemia (e.g., UGT1 A1 deficient mice or Gunn rat model of neonatal jaundice) will help to verify the potential of this nanoparticle in preclinical studies more strongly and lead the way to clinical trials. Finally, it is concluded, in view of good safety margin and faster action with the proposed nanomedicine (NPs), that the medicine could become the symptomatic treatment of choice in hyperbilirubinemia in general.
